Key result
Immunofluorescent labeling of collagen VI in fibroblast cultures predicted COL6A mutations with 100% sensitivity, 63% specificity, 75% positive predictive value, and 100% negative predictive value.
Why the study?
Does immunofluorescent labeling of collagen VI in fibroblast cultures accurately diagnose Bethlem myopathy?
Population
40 patients, including those with genetically confirmed Bethlem myopathy and a prospective group with…
Comparison
Immunofluorescent labeling of collagen VI in… vs Dual immunofluorescence for collagen VI and…
Design
Cross-sectional, blinded investigators
Authors
Loading...
Supports ruling out COL6A mutations via high sensitivity and NPV; leaves open prospective validation before guiding genetic testing in Bethlem myopathy.
Observational (n=40)
Blinded investigators
Does immunofluorescent labeling of collagen VI in fibroblast cultures accurately diagnose Bethlem myopathy?
Effect estimate: 100% sensitivity, 63% specificity
Immunofluorescent labeling of collagen VI in fibroblast cultures is a highly sensitive diagnostic tool that can effectively guide molecular genetic testing for Bethlem myopathy.
Hicks et al. (2008) conducted an observational in Bethlem myopathy (n=40). Immunofluorescent labeling of collagen VI in fibroblast cultures vs. Dual immunofluorescence in muscle / genetic findings was evaluated on Presence of a COL6A mutation (100% sensitivity, 63% specificity). Immunofluorescent labeling of collagen VI in fibroblast cultures predicted COL6A mutations with 100% sensitivity, 63% specificity, 75% positive predictive value, and 100% negative predictive value.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: